

16. (New) The method according to claim 15, wherein the compound is administered to a subject having a disorder associated with higher than normal blood glucose levels.

17. (New) The method according to claim 16 wherein the disorder is selected from type I or type II diabetes.

18. (New) The method according to claim 15 wherein the compound is a polypeptide comprising the 16 mer amino acid sequence PEWPSYLGYEKLYPYY, or a fragment or variant thereof which is capable of binding phosphorylase a.

19. (New) The method according to claim 18 wherein the polypeptide increases the activity of hepatic glycogen synthase. --

Respectfully submitted,

January 20, 2003
Date

Karla M. Weyand
Karla M. Weyand
Registration No. 40,223

Braman & Rogalskyj, LLP
P.O. Box 352
Canandaigua, New York 14424-0352
Tel: 716-626-5380
Fax: 716-626-5384

1:\002\00140\B2